Atalante X, a self-balancing robotic exoskeleton system, features a powered ankle mechanism. It can perform complex ankle movements that enable wearers to mimic a natural human gait. This helps therapists better assist patients in their rehabilitation.

Clearance comes just weeks after the New York-based robotic exoskeleton developer received expanded CE mark approval as well. The FDA expanded Atalante X’s indications to include individuals with spinal cord injury (SCI) from levels C4 to L5 and in those with multiple sclerosis (MS). This broadens access to upright, hands-free gait therapy.